Clinical Trials

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05991388 2026-02-20

Glo-BNHL

Phase 2/3 Recruiting

210 enrolled

Lymphoma, B-Cell

NCT05389423 2026-02-19

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

25 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT06350318 2026-02-05

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

43 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04884035 2026-02-04

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

174 enrolled

Phase EARLY_PHASE1 Recruiting

Lymphoma, B-Cell

NCT04161248 2026-02-02

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

18 enrolled

Lymphoma, B-Cell

NCT07097363 2026-01-15

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

18 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07270835 2025-12-08

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

Phase 4 Recruiting

40 enrolled

LymphoidMyeloid

Lymphoma, B-Cell, Lymphohistiocytosis, Hemophagocytic

NCT07081022 2025-08-21

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

180 enrolled

Lymphoma, B-Cell

NCT07073833 2025-07-18

The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma

40 enrolled

Lymphoma, B-Cell

NCT06954805 2025-05-02

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

30 enrolled

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT06251180 2025-03-25

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

112 enrolled